Navigation Links
Omeros to Present at the BioCentury NewsMakers Conference
Date:10/15/2010

SEATTLE, Oct. 15 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the BioCentury NewsMakers in the Biotech Industry Conference on October 22, 2010 at 1:30 p.m. Eastern time in New York City. The presentation will be webcast. The live or archived webcast can be accessed on the "Events" page of the Company's website at www.omeros.com.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery(TM) platform, the most advanced of which is in a Phase 3 clinical program, and one from its Addiction program. Omeros may also have the near-term capability, through its GPCR program, to add wholly new drug targets to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of antibody and small-molecule preclinical programs targeting inflammation and central nervous system disorders.


'/>"/>
SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , Mar. 29, 2017 Research and Markets ... Market 2017-2021" report to their offering. ... The global energy-based aesthetic devices market ... The report, Global Energy-Based Aesthetic Devices Market 2017-2021, ... from industry experts. The report covers the market landscape and its ...
(Date:3/29/2017)... Avelas Biosciences, Inc., a clinical stage oncology-focused company dedicated to improving ... Carmine N. Stengone , president and chief executive officer, will present ... th Annual Healthcare Conference on Wednesday, April 5, 2017, at ... Hotel in New York City . ... ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced the ... Therapy Centers & Forecast" report to their offering. ... Proton Therapy Market in Italy ... value in 2016. There are currently three proton therapy centers in ... more patients. In Italy , the first patients were ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... ... from Greet, S.C., wants to offer people a new way to care for their feet. ... so I know the importance of proper foot care," he said. "In order to enable ... The FOOT-TRAN SYSTEM enables a user to clean and exfoliate the bottoms of his or ...
(Date:3/30/2017)... Washington, DC (PRWEB) , ... March 30, 2017 ... ... scientists and organizations submitted a letter to President Trump expressing their support for ... two medical doctors, two Ph.D. scientists and one medical journalist, will hold a ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, ... each year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, ... efforts focus on finding more effective treatment options, the San Diego Gamma Knife ...
(Date:3/29/2017)... ... 30, 2017 , ... Grass pollen is the main cause of hay fever in the United ... for grass pollen runs from May to July each year; with the worst time for ... HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense against grass pollen; they ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its founder, Kathy Heshelow, are ... it has been used for thousands of years. , "The West has caught on, ... " Turmeric: How to Use it For Your Wellness. Overcome Inflammation, Enemy of the ...
Breaking Medicine News(10 mins):